🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Fascinating data from FOURIER presented by Yumi Kang, MD, PhD, MPH at #ESCCongress2024! Efficacy of PCSK9 mAb in patients with obesity - excess MACE risk conferred by obesity is attenuated by evolocumab. ARR 5.7% in those w BMI >35 at baseline! #ESCCongress

Evolocumab appears to attenuate the excess risk of MACE in patients with obesity. Yumi Kang, MD, PhD, MPH Michelle O'Donoghue Robert Giugliano #ESCCongress

Congratulations, Sid M. Patel, on delivering this important message for our patients! Your leadership and guidance continue to inspire us all.

"Lipoprotein(a) and cardiovascular disease" review published today in The Lancet: 50 days' free access: authors.elsevier.com/a/1jlsNV-4XOtaS Please share and resend for others to download. Bottom line: measure Lp(a) in all once in a lifetime and stay tuned for coming Lp(a)-lowering therapy!

[ESC 2024] 암젠 레파타, 비만 환자에서 더 큰 이득 제공 newsmp.com/news/articleVi…

What an incredible experience learning from and being trained by these visionaries! Forever grateful. TIMI Study Group

It is a huge honor to celebrate the 40 years of TIMI’s history with these visionaries #EugeneBraunwald #MarcSabatine TIMI Study Group Brigham and Women's Hospital

Robert Giugliano with a wonderful talk around new acs and pci guidelines Here are the 13 new class 1 recommendations in European Society of Cardiology guidelines Joint meeting of Coronary Revascularization meeting

Nerding out on glycemic control in the ACS setting in front of esteemed interventional cardiologists. #JCR #Busan

#Perspective Celebrating 40 years of success with the TIMI Study Group: origin and future directions TIMI Study Group ahajournals.org/doi/full/10.11…

In patients with atrial fibrillation and moderate-to-high risk of stroke, abelacimab, a monoclonal antibody that inhibits activation of factor XI, led to fewer bleeding events than rivaroxaban. Read the full AZALEA–TIMI 71 trial results: nej.md/3PJcknN #AFib

Coverage in MedPage Today of AZALEA-TIMI 71 primary results. #abelacimab Robert Giugliano Sid M. Patel medpagetoday.com/cardiology/arr…

Original Article: “Long-Term Cognitive Safety of Achieving Very Low LDL Cholesterol with Evolocumab” by André Zimerman et al. eviden.cc/3P3AmcQ Robert Giugliano TIMI Study Group #Cardiology #ClinicalTrials

I’m deeply grateful to have been part of this important work, led by my talented colleague Matt Lee, that now demonstrates a more consistent signal towards a greater CV benefit among Asian ppl w/T2D —with much narrower 95% CI! diabetesjournals.org/care/article/4…

There doesn’t appear to be a floor with LDL—💥 lower is better, even in the elderly. Check out our work in JACC Journals sciencedirect.com/science/articl…

Updated 2025 ACC/AHA ACS Guidelines now released! Congratulations to Michelle O'Donoghue, TIMI Senior Investigator, who served as Co-Chair. ahajournals.org/doi/10.1161/CI…

Great deep dive into cardiometabolic health in Asian populations and the heterogeneity in CV effects of GLP-1 RAs by race. Delivered by three Asian experts I admire. Tune in at 15:30! 🎧 Matthew MY Lee Dr. Alice Cheng #NaveedSattar

Beyond the❤️: GLP-1 RAs also reduce non-CV mortality. Meta-analysis of 11 CVOTs (n=90,867) shows ↓ in all-cause, CV, and non-CV deaths in people with T2DM/obesity. Yumi Kang, MD, PhD, MPH dom-pubs.onlinelibrary.wiley.com/doi/abs/10.111…

Honor to work with my visionary cardiologist mentors who also know how to think outside the ❤️ Ben Scirica #MarcSabatine TIMI Study Group

Clinical benefit of PCK9i inhibition in people with T1DM - Manuscript can be found at diabetesjournals.org/care/article-a…